Physician profile
Matthew A Geller
NPI 1346317013
$2,036.79
in general payments reported to CMS, 2019-2025
17 companies · $826 in 2025
The $826 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $97.45 · 2021: $218 · 2022: $55.79 · 2023: $275 · 2024: $89.77 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $747.74 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $238.26 | 2019-2024 | Invega Sustenna |
| Alkermes, INC. | $209.68 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.69 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $123.74 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $109.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $94.50 | 2023-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $88.31 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $77.93 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $64.02 | 2019-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $47.82 | 2019-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $33.67 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $21.02 | 2025 | |
| Braeburn INC. | $16.62 | 2025 | Brixadi |
| Shire North American Group INC | $14.44 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.95 | 2020 | |
| Life Molecular Imaging LTD | $9.86 | 2024 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.